Vyteris and Georgia Tech partner for transdermal drug delivery technologies

Vyteris, a developer of transdermal drug delivery technology, has announced an agreement with the Georgia Tech Research Corporation of the Georgia Institute of Technology, or Georgia Tech, granting Vyteris the option to exclusively license Georgia Tech's patented thermal ablation and microdevice fabrication technologies for transdermal drug delivery.

Under terms of the agreement, Georgia Tech will be entitled to royalty and milestone payments connected to the development and potential commercialization of products which incorporate the technologies. Specific financial terms of the agreement were not disclosed.

Vyteris plans to work closely with Georgia Tech to identify therapies that would be appropriate for the application of the new transdermal drug delivery technologies.



Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying